Positive Phase II Data for Macugen®

There are many reasons why here in Colorado we keep a careful eye on Macugen, no pun intended…

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced interim Phase II study results showing that injections of Macugen® resulted in better visual acuity outcomes in patients with macular edema due to central retinal vein occlusion compared with those receiving a sham injection. Over 90 percent of patients maintained or improved vision at 30 weeks when treated with Macugen® injections compared to approximately 69 percent of those treated in the control arm. Patients treated with Macugen for 30 weeks had, on average, an improvement in visual acuity while the control group demonstrated a mean decrease in visual acuity from baseline to week 30. Vision gain was seen with a single injection of Macugen® within 6 weeks of treatment, versus a loss in the control group.